Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background A polygenic risk score (PRS) is derived from a genome-wide association study (GWAS) and represents an aggregate of thousands of single-nucleotide polymorphisms (SNPs) that provide a baseline estimate of an individual’s genetic risk for a specific disease or trait at birth. Cardiometabolic disease represents a set of disease processes that historically have disproportionally affected underrepresented racial and minority groups. Furthermore, these groups represent a population generally not well captured by traditional risk scores compared to European cohorts. Since the first GWAS studying myocardial infarction was published, PRSs have increasingly been seen as a promising tool to improve risk stratification of non-European populations. However, how PRSs can be best used in clinical practice remains unclear. Purpose To provide an overview of the PRSs related to cardiometabolic disease, analyze the ancestral diversity of GWAS cohorts, and discuss the evidence supporting their clinical applications. Methods The Preferred Reporting Items For Systematic Reviews and Meta-analysis extension for Scoping Reviews protocol was used to conduct a scoping review of the MEDLINE, EMBASE, and CENTRAL databases. English studies that published a PRS related to atrial fibrillation (AF), cerebrovascular disease (CVD), coronary artery disease (CAD), dyslipidemia, heart failure, heritable cardiomyopathy, hypertension, and type 2 diabetes were reviewed. Results Across the 4,863 studies screened, 82 articles met the inclusion criteria. The most common PRS related to CAD, followed by hypertension and CVD. Limited ancestral diversity was observed as most studies (56) included only individuals of European ancestry. A smaller proportion of studies (16) published PRSs derived in multi-ancestry cohorts. Only ten studies published a PRS derived solely from a sample population of non-European ancestry (Chinese, East Asian, Japanese, and Korean). The predictive performance of most PRSs was similar to or superior to traditional risk factors. More than half of the included studies (42) reported an integrated risk model combining a PRS with traditional risk factors or a clinical risk tool (FRS, PCE, CHADS2). The integrated risk model consistently improved predictive accuracy, but few studies investigated the performance in a non-European population. Conclusion In conclusion, this scoping review is the first of its kind and reports strong evidence for the clinical use of PRSs in AF, CAD, CVD, and hypertension. However, most PRSs are derived in cohorts of European ancestry, which contributes to a lack of PRS transferability across different ancestral groups, likely exacerbating health inequities. Future prospective studies should focus on further establishing the clinical utility of PRSs. Additionally, diversity in future GWAS cohorts is essential to ensure that PRSs reflect the multi-ancestry society at large.

Clinical and Genetic Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke

Polygenic risk scores in atrial fibrillation: associations and clinical utility in disease prediction

Determinants of Left Atrial Thrombus or Spontaneous Echo Contrast in Nonvalvular Atrial Fibrillation

Association between genetic predisposition of AF and the risk of ischemic stroke and thromboembolism

Abstract P200: A Polygenic Risk Score Improves Prediction Of Lifetime Risk For Heart Failure

A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure

Integrating Clinical, Genetic, and Electrocardiogram-Based Artificial Intelligence to Estimate Risk of Incident Atrial Fibrillation

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease

Abstract P339: The Clinical Application and Ancestral Diversity of Cardiometabolic Polygenic Risk Scores

Development and Validation of a Polygenic Risk Score for Stroke in the Chinese Population

New Perspective on the Risk Markers for Left Atrial Thrombosis in Patients with Atrial Fibrillation.

Abstract P656: Cardioembolic Risk Factors and Ischemic Stroke a Mendelian Randomization Analysis

A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients.

Clinical use of polygenic risk scores for detection of peripheral artery disease and cardiovascular events

Combined polygenic scores for ischemic stroke risk factors aid risk assessment of ischemic stroke

Abstract 10816: Causal Effect of Atrial Fibrillation on Cardiovascular Diseases - A Mendelian Randomization Analysis in the Million Veteran Program

Enhanced prediction of atrial fibrillation risk using proteomic markers: a comparative analysis with clinical and polygenic risk scores

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Performance of Atrial Fibrillation Burden Trends for Stroke Risk Stratification

Multimodal Approach for the Prediction of Atrial Fibrillation Detected After Stroke: SAFAS Study

The current state and future of cardiometabolic polygenic risk scores in European and non-European population cohorts